Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 28;4(1):119-125.
doi: 10.1016/j.ekir.2018.09.015. eCollection 2019 Jan.

Clinical and Genetic Characteristics in Patients With Gitelman Syndrome

Affiliations

Clinical and Genetic Characteristics in Patients With Gitelman Syndrome

Junya Fujimura et al. Kidney Int Rep. .

Abstract

Introduction: Gitelman syndrome (GS) is a tubulopathy exhibited by salt loss. GS cases are most often diagnosed by chance blood test. Aside from that, some cases are also diagnosed from tetanic symptoms associated with hypokalemia and/or hypomagnesemia or short stature. As for complications, thyroid dysfunction and short stature are known, but the incidence rates for these complications have not yet been elucidated. In addition, no genotype-phenotype correlation has been identified in GS.

Methods: We examined the clinical characteristics and genotype-phenotype correlation in genetically proven GS cases with homozygous or compound heterozygous variants in SLC12A3 (n = 185).

Results: In our cohort, diagnostic opportunities were by chance blood tests (54.7%), tetany (32.6%), or short stature (7.2%). Regarding complications, 16.3% had short stature, 13.7% had experienced febrile convulsion, 4.3% had thyroid dysfunction, and 2.5% were diagnosed with epilepsy. In one case, QT prolongation was detected. Among 29 cases with short stature, 10 were diagnosed with growth hormone (GH) deficiency and GH replacement therapy started. Interestingly, there was a strong correlation in serum magnesium levels between cases with p.Arg642Cys and/or p.Leu858His and cases without these variants, which are mutational hotspots in the Japanese population (1.76 mg/dl vs. 1.43 mg/dl, P < 0.001).

Conclusion: This study has revealed, for the first time, clinical characteristics in genetically proven GS cases in the Japanese population, including prevalence of complications. Patients with hypokalemia detected by chance blood test should have gene tests performed. Patients with GS need attention for developing extrarenal complications, such as short stature, febrile convulsion, thyroid dysfunction, epilepsy, or QT prolongation. It was also revealed for the first time that hypomagnesemia was not severe in some variants in SLC12A3.

Keywords: QT prolongation; SLC12A3; febrile convulsion; salt-losing tubulopathy; thyroid.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Diagnostic opportunities for Gitelman syndrome. Among 185 cases, 4 were excluded because they were unclear (n = 181). Opportunities for diagnosis were blood test by chance (54.7%), tetany symptoms (32.6%), screening examination for short stature (7.2%), or family history (5.5%).
Figure 2
Figure 2
Growth after growth hormone (GH) supplementation in 5 patients with GH deficiency. Lines show SD changes in height after starting GH replacement therapy. Three cases showed remarkable improvement, but 2 showed no effect, possibly because of the short treatment period.
Figure 3
Figure 3
Differences in serum magnesium levels and fractional excretion of magnesium (FEMg) between cases with and without hotspot mutations. Patients were divided into 3 groups: no, 1, or 2 mutational hotspots. (a) Serum magnesium levels showed significant differences among all 3 groups. (b) No significant differences were detected regarding FEMg.

Similar articles

Cited by

References

    1. Kurtz I. Molecular pathogenesis of Bartter's and Gitelman's syndromes. Kidney Int. 1998;54:1396–1410. - PubMed
    1. Simon D.B., Nelson-Williams C., Bia M.J. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet. 1996;12:24–30. - PubMed
    1. Mastroianni N., Bettinelli A., Bianchetti M. Novel molecular variants of the Na-Cl cotransporter gene are responsible for Gitelman syndrome. Am J Hum Genet. 1996;59:1019–1026. - PMC - PubMed
    1. Balavoine A.S., Bataille P., Vanhille P. Phenotype-genotype correlation and follow-up in adult patients with hypokalaemia of renal origin suggesting Gitelman syndrome. Eur J Endocrinol. 2011;165:665–673. - PubMed
    1. Cruz D.N., Shaer A.J., Bia M.J. Gitelman's syndrome revisited: an evaluation of symptoms and health-related quality of life. Kidney Int. 2001;59:710–717. - PubMed